First line chemotherapy of metastatic breast cancer
نویسندگان
چکیده
منابع مشابه
First line chemotherapy of metastatic breast cancer.
In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.
متن کاملFirst-Line Chemotherapy for Advanced Breast Cancer.
First-line chemotherapy for metastatic breast cancer has been the focus of ongoing controversy, a condition that partially reflects the imperfections of available therapy. It also partially reflects not only the imperfections in our ability to monitor response, but also the disagreements among clinicians over the goals of therapy. Each physician maintains a hierarchy of goals for the treatment ...
متن کاملAdvances in the management of metastatic breast cancer: options beyond first-line chemotherapy.
This article provides an overview of recent advances in chemotherapy that may be used for the treatment of patients with locally advanced or metastatic breast cancer (MBC). Key phase ii and iii trial data for eribulin mesylate, ixabepilone, and nab-paclitaxel, published since 2006, are discussed on the basis of recency, depth, and quality.Eribulin mesylate is the first monotherapy to significan...
متن کاملBody mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.
BACKGROUND The effect of body mass index (BMI) on the prognosis of metastatic breast cancer (MBC) has not been explored so far. METHODS The relationship between BMI (kg/m(2)) and progression-free survival (PFS) or overall survival (OS) was assessed in 489 patients with MBC enrolled in three clinical trials of first-line chemotherapy. World Health Organization BMI categories were used: normal,...
متن کاملPrognostic Factors for First-Line Chemotherapy Treated Metastatic Gastric Cancer
Despite the reduced incidence, gastric cancer is the second most common among cancer-related deaths in the word. In two-third of patients with gastric cancer are diagnosed with metastatic disease (Kamangar et al., 2006; Jemal et al., 2011). Without effective treatment, the median survival for metastatic disease is 3 to 5, however it may be extended 8-12 months with the platinum and taxane-conta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2006
ISSN: 0923-7534
DOI: 10.1093/annonc/mdj974